Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods of preparing Anti-human papillomavirus antigen t cells

a technology of human papillomavirus and antigen t cells, which is applied in the field of preparation of antihuman papillomavirus antigen t cells, can solve the problems of poor prognosis of many cancers, including hpv-associated cancers

Inactive Publication Date: 2016-05-26
US DEPT OF HEALTH & HUMAN SERVICES
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes methods for preparing and using a population of T cells that are specific for HPV (the virus associated with cervical cancer) and can recognize and attack cancer cells that express HPV. The methods involve dividing a tumor sample into smaller fragments, culturing each fragment separately, and obtaining T cells from the cultured fragments. These T cells are then tested for their ability to recognize both autologous HPV-positive tumors (tumors that the patient's body produces) and HPV antigens (the virus that causes cancer). Only the T cells that exhibit this recognition are selected and expanded in large numbers to create a population of HPV-specific T cells. These cells can then be administered to patients to treat or prevent cervical cancer.

Problems solved by technology

Despite advances in treatments such as chemotherapy, the prognosis for many cancers, including HPV-associated cancers, may be poor.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of preparing Anti-human papillomavirus antigen t cells
  • Methods of preparing Anti-human papillomavirus antigen t cells
  • Methods of preparing Anti-human papillomavirus antigen t cells

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0085]This example demonstrates a method of preparing HPV-positive tumor-infiltrating lymphocytes (TIL) for adoptive cell therapy.

[0086]Patients were entered into clinical protocols and signed informed consents that were approved by the Institutional Review Board of the National Cancer Institute prior to tumor resection. Tumors were excised from patients. Tumors were tested for HPV 16 E6, HPV 16 E7, HPV 18 E6, and HPV 18 E7 expression using reverse transcriptase (RT) polymerase chain reaction (PCR) genotyping.

[0087]Multiple (24) independent cultures of HPV 16 E6 positive, HPV E7 positive, HPV 18 E6 positive, and HPV E7 positive TIL were set up using enzymatic digests and tumor fragments (1-2 mm3) procured by sharp dissection. TIL from tumor digests were generated by culturing single-cell suspensions (5×105 / mL) obtained by overnight enzymatic digestion of tumor fragments in media containing collagenase, hyaluronidase, and DNAse. Cultures of tumor fragments and digests were initiated ...

example 2

[0091]This example demonstrates the reactivity of the TIL from Patient 1.

[0092]TIL were generated as described in Example 1 from 22 different tumor fragments (F1-F22) from Patient 1. The TIL from Patient 1 or melanoma TIL (control) were co-cultured with dendritic cells pulsed with the HPV 18 E7 peptide pool or a gp100 peptide pool (control) and IFN-γ was measured. The results are shown in FIGS. 1A-1B. As shown in FIGS. 1A-1B, the TIL from tumor fragment 22 of Patient 1 recognized an autologous tumor line but not HPV 18 E7 peptides.

[0093]The TIL from tumor fragments F16, F17, or F22 of Patient 1 or cells given to the patient for treatment (“infusion bag”) were co-cultured with autologous tumor, peripheral blood mononuclear cells (PBMC) from autologous tissue, tumor cells matched at all class I loci, HeLa cells (HLA mismatched), or CaSki cells (HLA mismatched). IFN-γ was measured. The results are shown in FIG. 2A. As shown in FIG. 2A, TIL from tumor fragments F16 and F22 showed autolo...

example 3

[0097]This example demonstrates the cloning of TIL from tumor fragment 16 of Patient 1 to isolate HPV 18 E7 reactive CD8 positive T cells.

[0098]DCs were loaded with HPV 18 E7 and co-cultured with TIL from tumor fragment 16 (F16) of Patient 1. The TIL were sorted for 4-1BB positive cells using fluorescence activated cell sorting (FACS). The sorted cells were cultured in 96-well plates with two cells per well. The clones were screened for tumor reactivity against a gp100 peptide pool or a HPV 18 E7 peptide pool. The results are shown in FIGS. 4A and 4B. As shown in FIGS. 4A and 4B, CD8 positive T cell cloning from tumor fragment F16 using 4-1BB-based FACS sorting resulted in the isolation of two clones (12 and 21) with E7 peptide pool reactivity.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]This patent application claims the benefit of U.S. Provisional Patent Application No. 61 / 846,161, filed Jul. 15, 2013, which is incorporated herein by reference in its entirety.BACKGROUND OF THE INVENTION[0002]The primary cause of some cancer types such as, for example, uterine cervical cancer, is human papillomavirus (HPV) infection. Despite advances in treatments such as chemotherapy, the prognosis for many cancers, including HPV-associated cancers, may be poor. Accordingly, there exists an unmet need for additional treatments for cancer, particularly HPV-associated cancers.BRIEF SUMMARY OF THE INVENTION[0003]An embodiment of the invention provides a method of preparing a population of HPV-specific T cells, the method comprising: dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments in the presence of only one cytokine; obtaining T cells from the cultured multiple fragments; testing th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/12C12N7/00C12N5/0783
CPCA61K39/12C12N5/0638C12N7/00A61K2039/5158C12N2710/20011A61K2039/572C12N2501/2302C12N2502/30A61K2039/585C12N5/0636A61P1/04A61P11/04A61P15/00A61P15/02A61P35/00A61K39/464838A61K39/4611A61K39/464492C12N7/025A61K35/17
Inventor HINRICHS, CHRISTIAN S.ROSENBERG, STEVEN A.
Owner US DEPT OF HEALTH & HUMAN SERVICES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com